The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic

The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic Publisher Pubmed

Azimzadeh M¹ ; Mohn N² ; Ghane Ezabadi S³ ; Moghimi Esfandabadi Z⁴ ; Soleimani A⁵ ; Ranjbar E⁶ ; Jahromi M⁷ ; Seyedebrahimi R⁸ ; Skripuletz T² ; Moharrami Kasmaie F⁹

Show Affiliations

1. Department of Medical Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran
2. Department of Neurology, Hannover Medical School, Hannover, 30625, Germany
3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
4. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Medical Laboratory Sciences, Faculty of Paramedicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
6. Department of Paramedical Sciences, Gonabad University of Medical Sciences, Gonabad, Iran
7. Department of Anatomical Science, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran
8. Department of Anatomical Sciences, School of Medicine, Qom University of Medical Sciences, Qom, Iran
9. Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Biomolecules Published:2021

Abstract

A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Related Docs

View other Related Docs

1. Risk Factors for Adverse Outcomes of Covid-19 Patients: Possible Basis for Diverse Responses to the Novel Coronavirus Sars-Cov-2, Life Sciences (2021)

2. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)

3. The Contributory Role of Lymphocyte Subsets, Pathophysiology of Lymphopenia and Its Implication As Prognostic and Therapeutic Opportunity in Covid-19, International Immunopharmacology (2021)

4. Pathological Effects of Sars-Cov-2 on Hematological and Immunological Cells: Alterations in Count, Morphology, and Function, Pathology Research and Practice (2022)

5. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)

6. Are Patients With Multiple Sclerosis (Ms) at Higher Risk of Covid-19 Infection?, Neurological Sciences (2020)

7. Immunosenescence and Inflamm-Ageing in Covid-19, Ageing Research Reviews (2023)

8. Storm at the Time of Corona: A Glimpse at the Current Understanding and Therapeutic Opportunities of the Sars-Cov-2 Cytokine Storm, Current Pharmaceutical Design (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (41)

Mohammad Ali Sahraian (37)

Style	Citing Format
MLA	Azimzadeh M, et al.. "The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic." Biomolecules, vol. 11, no. 9, 2021, pp. -.
APA	Azimzadeh M, Mohn N, Ghane Ezabadi S, Moghimi Esfandabadi Z, Soleimani A, Ranjbar E, Jahromi M, Seyedebrahimi R, Skripuletz T, Moharrami Kasmaie F (2021). The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic. Biomolecules, 11(9), -.
Chicago	Azimzadeh M, Mohn N, Ghane Ezabadi S, Moghimi Esfandabadi Z, Soleimani A, Ranjbar E, Jahromi M, Seyedebrahimi R, Skripuletz T, Moharrami Kasmaie F. "The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic." Biomolecules 11, no. 9 (2021): -.
Harvard	Azimzadeh M et al. (2021) 'The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic', Biomolecules, 11(9), pp. -.
Vancouver	Azimzadeh M, Mohn N, Ghane Ezabadi S, Moghimi Esfandabadi Z, Soleimani A, Ranjbar E, et al.. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic. Biomolecules. 2021;11(9):-.
BibTex	@article{ author = {Azimzadeh M and Mohn N and Ghane Ezabadi S and Moghimi Esfandabadi Z and Soleimani A and Ranjbar E and Jahromi M and Seyedebrahimi R and Skripuletz T and Moharrami Kasmaie F}, title = {The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic}, journal = {Biomolecules}, volume = {11}, number = {9}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Azimzadeh M AU - Mohn N AU - Ghane Ezabadi S AU - Moghimi Esfandabadi Z AU - Soleimani A AU - Ranjbar E AU - Jahromi M AU - Seyedebrahimi R AU - Skripuletz T AU - Moharrami Kasmaie F TI - The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic JO - Biomolecules VL - 11 IS - 9 SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract